| 29/04/22 | 17:30:04 | 29 Apr 2022 | | Result of AGM |
| 29/04/22 | 07:05:01 | 29 Apr 2022 | | AstraZeneca plans new R&D centre in Massachusetts |
| 29/04/22 | 07:00:03 | 29 Apr 2022 | | First quarter 2022 results |
| 28/04/22 | 07:00:12 | 28 Apr 2022 | | Ultomiris approved in the US for adults with gMG |
| 27/04/22 | 07:00:11 | 27 Apr 2022 | | Enhertu granted BTD for HER2-low breast cancer |
| 25/04/22 | 07:00:08 | 25 Apr 2022 | | Tremelimumab US Priority Review for Imfinzi combo |
| 19/04/22 | 07:00:11 | 19 Apr 2022 | | Enhertu granted Priority Review for HER2m NSCLC |
| 01/04/22 | 15:00:05 | 1 Apr 2022 | | Total Voting Rights |
| 29/03/22 | 07:00:09 | 29 Mar 2022 | | Ondexxya approved in Japan for FXai reversal |
| 28/03/22 | 07:00:09 | 28 Mar 2022 | | Evusheld approved in the EU for COVID-19 |
| 25/03/22 | 15:30:06 | 25 Mar 2022 | | Director/PDMR Shareholding |
| 24/03/22 | 18:00:06 | 24 Mar 2022 | | Evusheld Positive EU CHMP Opinion |
| 24/03/22 | 07:00:10 | 24 Mar 2022 | | Update on CALLA Phase III trial for Imfinzi |
| 23/03/22 | 11:00:02 | 23 Mar 2022 | | Notice of AGM |
| 17/03/22 | 07:00:05 | 17 Mar 2022 | | Settlement of patent litigation for Ultomiris |
| 14/03/22 | 07:05:07 | 14 Mar 2022 | | Lynparza approved in US for early breast cancer |
| 14/03/22 | 07:00:11 | 14 Mar 2022 | | Update on US review of Fasenra in nasal polyps |
| 09/03/22 | 15:30:01 | 9 Mar 2022 | | Director/PDMR Shareholding |
| 07/03/22 | 15:30:01 | 7 Mar 2022 | | Director/PDMR Shareholding |
| 01/03/22 | 15:30:01 | 1 Mar 2022 | | Director/PDMR Shareholding |
| 01/03/22 | 15:00:01 | 1 Mar 2022 | | Total Voting Rights |
| 01/03/22 | 07:00:06 | 1 Mar 2022 | | AstraZeneca and Neurimmune close deal for NI006 |
| 23/02/22 | 07:00:02 | 23 Feb 2022 | | Filing of Form 20-F with SEC |
| 22/02/22 | 11:00:00 | 22 Feb 2022 | | Chair succession planning update and Annual Report |
| 21/02/22 | 07:00:09 | 21 Feb 2022 | | Enhertu improves PFS and OS in HER2-low BC |
| 16/02/22 | 07:00:08 | 16 Feb 2022 | | Saphnelo approved in EU for SLE |
| 15/02/22 | 07:00:06 | 15 Feb 2022 | | Lynparza combo delays progression risk in prostate |
| 11/02/22 | 15:30:02 | 11 Feb 2022 | | Director/PDMR Shareholding |
| 10/02/22 | 07:00:03 | 10 Feb 2022 | | AZN: Full year and Q4 2021 results |
| 01/02/22 | 15:00:05 | 1 Feb 2022 | | Total Voting Rights |
| 19/01/22 | 07:05:08 | 19 Jan 2022 | | Imfinzi improves survival in biliary tract cancer |
| 19/01/22 | 07:00:07 | 19 Jan 2022 | | Imfinzi combo shows unprecedented survival in HCC |
| 17/01/22 | 07:00:07 | 17 Jan 2022 | | Enhertu granted Priority Review for breast cancer |
| 07/01/22 | 07:00:07 | 7 Jan 2022 | | AstraZeneca and Neurimmune sign deal for NI006 |
| 05/01/22 | 07:00:08 | 5 Jan 2022 | | Transfer of rights to Eklira, Duaklir completed |
| 04/01/22 | 15:00:07 | 4 Jan 2022 | | Total Voting Rights |
| 29/12/21 | 07:00:11 | 29 Dec 2021 | | AstraZeneca and Ionis close eplontersen deal |
| 21/12/21 | 07:00:05 | 21 Dec 2021 | | Ultomiris accepted for FDA Priority Review for gMG |
| 20/12/21 | 07:05:06 | 20 Dec 2021 | | Tezspire approved in the US for severe asthma |
| 20/12/21 | 07:00:07 | 20 Dec 2021 | | Saphnelo recommended for EU approval for SLE |
| 15/12/21 | 15:00:01 | 15 Dec 2021 | | Director/PDMR Shareholding |
| 09/12/21 | 07:00:06 | 9 Dec 2021 | | Evusheld US FDA EUA |
| 07/12/21 | 07:00:04 | 7 Dec 2021 | | AstraZeneca, Ionis to collaborate on eplontersen |
| 01/12/21 | 15:00:06 | 1 Dec 2021 | | Block listing Interim Review |
| 01/12/21 | 15:00:06 | 1 Dec 2021 | | Total Voting Rights |
| 30/11/21 | 07:00:06 | 30 Nov 2021 | | Lynparza granted FDA Priority Review for OlympiA |
| 15/11/21 | 16:00:05 | 15 Nov 2021 | | Director/PDMR Shareholding |
| 12/11/21 | 07:00:02 | 12 Nov 2021 | | AZN: Year to date and Q3 2021 results |
| 01/11/21 | 15:00:01 | 1 Nov 2021 | | Total Voting Rights |
| 01/11/21 | 07:00:12 | 1 Nov 2021 | | AstraZeneca to transfer rights to Eklira, Duaklir |
